Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial

  title={Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial},
  author={Andrew I. R. Maas and Gordon Murray and Herbert R. Henney and Nadim Kassem and Val{\'e}rie Legrand and Miriam Mangelus and Jan Paul Muizelaar and Nino Stocchetti and Nachshon Knoller},
  journal={The Lancet Neurology},

Figures and Tables from this paper

Prostacyclin treatment and clinical outcome in severe traumatic brain injury patients managed with an ICP-targeted therapy: A prospective study
With this treatment protocol, a low number of deaths and a high number of favourable outcomes in sTBI were observed, and ICPmax is a positive predictor of worse outcome.
Incidence and impact of withdrawal of life-sustaining therapies in clinical trials of severe traumatic brain injury: A systematic review
Given the high proportion of deaths due to the withdrawal of life-sustaining therapies in severe traumatic brain injury patients, and the potential of this medical decision to influence the results of clinical trials, instances of withdrawal should be systematically reported in clinical trials in this group of patients.
Observer variation in outcome assessment is a significant problem for head injury trials and can be improved by standardizing procedures, training assessors, and monitoring the quality of assessments and providing feedback to interviewers.
Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury: The POLAR Randomized Clinical Trial
Among patients with severe traumatic brain injury, early prophylactic hypothermia compared with normothermic management did not improve neurologic outcomes at 6 months, and these findings do not support the use of early proPHylactic Hypothermia for patients withsevere traumatic brain injuries.
Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study.
The occurrence of secondary insults prior to or on admission to hospital in TBI patients is strongly related to poorer outcome and should therefore be a priority for emergency department personnel.
Effect of Marijuana Use on Outcomes in Traumatic Brain Injury
A positive THC screen is associated with decreased mortality in adult patients sustaining TBI and a THC(+) screen was independently associated with survival after TBI.
Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature
While there is currently no single pharmacological therapy that will unequivocally improve clinical outcomes after TBI, several agents have demonstrated promising clinical benefits for specific TBI patients and should be investigated further.
Acute management of acquired brain injury part II: An evidence-based review of pharmacological interventions
Reviewing the research literature on pharmacological interventions used in the acute phase of acquired brain injury (ABI) to manage ICP and improve neural recovery found corticosteroids were found to be contraindicated and cannabinoids were reported as ineffective.
Pharmacological treatments for preventing epilepsy following traumatic head injury.
Treatment with an AED (phenytoin or carbamazepine) decreased the risk of early seizure compared with placebo or standard care and there was no evidence of a difference in therisk of late seizure occurrence between AEDs and placebo orstandard care.
IMPACT database of traumatic brain injury: design and description.
The design and content of the IMPACT database of traumatic brain injury is described, which contains the complete dataset from most clinical trials and organized epidemiologic studies conducted over the past 20 years, providing a unique resource for prognostic analysis and for studies aimed at optimizing the design and analysis of Phase III trials intraumatic brain injury.


Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.
Dexanabinol was safe and well tolerated in severe head injury and the treated patients achieved significantly better intracranial pressure/cerebral perfusion pressure control without jeopardizing blood pressure.
Lack of effect of induction of hypothermia after acute brain injury.
Treatment with hypothermia, with the body temperature reaching 33 degrees C within eight hours after injury, is not effective in improving outcomes in patients with severe brain injury.
Clinical trials in traumatic brain injury: current problems and future solutions.
Mechanistic and/or prognostic targeting, as well as possibilities for covariate adjustment, are suggested as possible solutions to deal with the problems of heterogeneity in clinical trials in TBI.
Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations
An overview of the results of recent trials of neuroprotective agents in head injury is presented. None of the trials showed efficacy in the general population of patients with a severe head injury.
Traumatic brain injury
Size and quality of randomised controlled trials in head injury: review of published studies
Abstract Objective: To assess whether trials in head injury are large enough to avoid moderate random errors and designed to avoid moderate biases. Design: All randomised controlled trials on the
Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers.
The pharmacokinetics of dexanabinol (HU-211), a synthetic, nonpsychotropic cannabinoid with neuroprotectant action, was evaluated in a phase I clinical trial and data are similar to those reported for naturally occurring cannabinoids such as delta 9-tetrahydrocannabinol and cannabidiol.
Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.
It is hypothesized that improper dissolution of the vehicle Cremophor EL may have been a cause for these anaphylactoid reactions during a phase I/II trial of high-dose intravenous cyclosporine (CsA) therapy to attenuate tumor multidrug resistance (MDR).